Bionano Genomics, Inc. announced its participation in the American Association for Cancer Research (AACR) Annual Meeting 2024 with a broad range of content covering the utility of OGM for cell bioprocessing quality control, solid tumor and hematological malignancy cancer research. AACR?s annual meeting brings together industry, medical, and academic professionals to discuss advances in cancer science and medicine. The AACR conference will be held April 5-10, 2024, in San Diego, California.

Bionano will introduce its new Stratys? system, which offers higher throughput and improved sample flexibility, to the cancer research community at the conference. The Company will also preview VIA?

7.1 software, an upcoming advancement to its software for visualization, interpretation and reporting of OGM, NGS, and microarray data. VIA 7.1 includes new and improved capabilities for cancer research, including automated detection and interpretation of aneuploidies at a 5% variant allele fraction, providing researchers with greater insights into tumor initiation, progression and treatment resistance. The software also features quality scores for SV detection, enhanced visualization for accurate interpretation of complex datasets with VIA Circos plots, and streamlined, customizable reporting options.

Nine scientific poster presentations will illustrate OGM?s utility for cancer research in areas including solid tumors, hematological malignancies, as well as applications in cell and gene therapy and cell manufacturing and bioprocessing quality control.